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Abstract
Introduction Phytoestrogens are a group of compounds found
in plants that structurally resemble the hormone oestradiol, and
thus have the potential to act as oestrogen agonists or
antagonists. Their potential effects may alter the risk of breast
cancer, but only a limited range of phytoestrogens has been
examined in prospective cohort studies.
Methods Serum and urine samples from 237 incident breast
cancer cases and 952 control individuals (aged 45 to 75 years)
in the European Prospective into Cancer-Norfolk cohort were
analysed for seven phytoestrogens (daidzein, enterodiol,
enterolactone, genistein, glycitein, o-desmethylangolensin, and
equol) using liquid chromatography/mass spectrometry. Data
on participants' diet, demographics, anthropometrics, and
medical history were collected upon recruitment. All models
were adjusted for weight, fat and energy intake, family history of
breast cancer, social class, analytical batch, and factors related
to oestrogen exposure.
Results Urinary or serum phytoestrogens were not associated
with protection from breast cancer in the European Prospective
into Cancer-Norfolk cohort. Breast cancer risk was marginally
increased with higher levels of total urinary isoflavones (odds
ratio = 1.08 (95% confidence interval = 1.00 to 1.16), P =
0.055); among those with oestrogen receptor-positive tumours,
the risk of breast cancer was increased with higher levels of
urinary equol (odds ratio = 1.07 (95% confidence interval =
1.01 to 1.12), P = 0.013).
Conclusion There was limited evidence of an association
between phytoestrogen biomarkers and breast cancer risk in the
present study. There was no indication of decreased likelihood
of breast cancer with higher levels of phytoestrogen biomarkers,
but the observation that some phytoestrogen biomarkers may be
associated with greater risk of breast cancer warrants further
study with greater statistical power.
Introduction
It has been proposed that phytoestrogens – dietary com-
pounds that structurally resemble the hormone oestrogen –
are associated with the development of breast cancer due to
their potential to act as oestrogen agonists or antagonists [1-
3]. Phytoestrogens are a complex group of compounds wide-
spread at low levels in most western plant foods. There are
two main classes: the isoflavones (daidzein, genistein, and gly-
citein), present at high levels in soya products [4]; and the lig-
nans (secoisolariresinol, matairesinol, pinoresinol, and
lariciresinol) found in wholegrain cereals, fruits and vegeta-
bles, and flaxseed [5,6]. O-Desmethylangolensin (O-DMA)
and equol are metabolites of daidzein, and enterodiol and
enterolactone are metabolites of lignans; the parent com-
pounds are metabolised by the gut flora. Both precursors and
metabolites can be measured in biological fluids [7].
EPIC = European Prospective into Cancer; ER = oestrogen receptor; O-DMA = o-desmethylangolensin.Breast Cancer Research    Vol 10 No 2    Ward et al.
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The proposed protective mechanisms of phytoestrogens
include stimulation of apoptosis, antioxidant activity, inhibition
of enzymes associated with carcinogenesis and steroid
metabolism, and competitive binding to oestrogen receptors
(ERs) [8-12]. Phytoestrogens, however, may be more likely to
demonstrate antiestrogenic behaviour when endogenous oes-
trogen is high, and to exhibit oestrogenic activity when circu-
lating endogenous oestrogen is low [2,13,14];
phytoestrogens may therefore be more strongly associated
with oestrogen-sensitive breast cancers. Of the phytoestro-
gens, the metabolite equol is more oestrogenic in in vitro
assays than its precursor daidzein, although only about one-
third of individuals are reported to be capable of producing
equol [7,15].
Serum and urinary biomarkers of phytoestrogen exposure
serve as an alternative indicator of dietary intake, and are
advantageous in that they are not reliant on self-reported die-
tary information or on food composition databases for phy-
toestrogen quantification. Furthermore, the use of biomarkers
reflects the variation across individuals in terms of gut micro-
flora, which is responsible for the production of equol and O-
DMA from its parent compound daidzein, and is influenced by
stress, diet, bowel disease, genetics, and antibiotic use among
other factors [15]. Studies to date have generally included a
limited range of phytoestrogen biomarkers, with the majority of
studies focused solely on enterolactone [16-21]. Depending
on the phytoestrogen under examination, risk for breast cancer
has appeared to be increased by [17,20-22], to be decreased
by [16,17,19,20,23-26] or not to be associated with [18,20-
25,27] higher serum or urinary levels. Previous assays in bio-
logical fluids have often suffered from complex, multistage
sample preparation, poor precision and substantial limitations
in the number of these complex analytes that could be
assessed at low levels found in biological fluids [15,22].
Using newly developed highly sensitive and rapid methods for
the analysis of phytoestrogens by mass spectrometry incorpo-
rating triply 13C-labelled standards for quantitation, we have
previously shown that phytoestrogens in plasma and serum
are closely correlated [22] and that odds ratios for equol expo-
sure were significantly increased in the relatively small Euro-
pean Prospective into Cancer (EPIC)-Norfolk cohort study (97
cases with serum and urine data, and 17 cases with urine data
only) [22]. In the Dutch arm of the EPIC study, however, an
inverse effect for plasma genistein (odds ratio = 0.68, 95%
confidence interval = 0.47 to 0.98) was detected among 383
cases and 383 control individuals, despite the use of the same
study design and laboratory methods as the EPIC-Norfolk
cohort [25]. We have therefore enlarged the EPIC-Norfolk
study to include a total of 237 cases matched with double the
numbers of control individuals. To our knowledge, this is the
largest study to date utilising accurate and sensitive mass
spectrometry methodology to assess phytoestrogen
exposure.
Materials and methods
Between 1993 and 1997, men and women aged 45 to 75
years were recruited from general practitioners' databases for
the EPIC-Norfolk study [28]. A health and lifestyle question-
naire was administered by mail, collecting data on smoking,
alcohol consumption, social class, basic family medical his-
tory, exercise, and reproductive history [28]. Participants com-
pleted 7-day diet diaries that were entered into an inhouse
dietary assessment software program – Data into Nutrients for
Epidemiological Research – to calculate average daily nutrient
intakes [29]. Height and weight measurements and blood
samples were collected as part of a health check conducted
by nurses. Spot urine and plasma serum were stored at -20°C
and -80°C, respectively, prior to analysis. Questionnaires and
health checks were completed by 25,639 healthy adults,
14,032 of whom were women. The study was approved by the
Norwich District Health Authority Ethics Committee, and all
participants gave signed informed consent.
The International Classification of Diseases, Injuries, and
Causes of Death was applied for the classification of incident
cases of invasive breast cancer (ICD9 174, ICD10 C50C).
Between 1993 and July 2006, there were 237 incident cases
of invasive breast cancer identified through the East Anglia
Cancer Registry, diagnosed a minimum of 12 months after
recruitment in the EPIC-Norfolk cohort.
Cases were matched with four control individuals based on
age (± 3 years) using the entire EPIC-Norfolk cohort prior to
the analysis of serum and urine phytoestrogen data. Serum
and urine samples were not available, however, for all of the
cases and control individuals; as a result, the number of con-
trols varied from one to four per case. For the present analysis
of phytoestrogens, therefore, the data were treated as fre-
quency matched and adjusted for age.
All 237 cases and 952 control individuals had completed a
food diary and had at least one blood or urine sample available
for analysis. The ER status of tumour samples was also
obtained from the East Anglia Cancer Registry. ER-positive
tumours were detected among 115 cases, ER-negative cases
were detected among 27 cases, and ER status information
was not available for 95 cases. Seventy-four per cent of cases
without ER status were from the first batch; this was probably
due to the fact that ER testing was not routinely conducted
until 1999. Plasma oestradiol was available for 153 cases and
603 control individuals using methods for estimating plasma
oestradiol published previously [30].
Serum samples, drawn at the health check, were analysed for
daidzein, genistein, glycitein, O-DMA, equol, enterodiol and
enterolactone. Samples were analysed as described previ-
ously [22]. Briefly, phytoestrogen metabolites were enzymati-
cally deconjugated and extracted using Strata C18-E SPE
cartridges (Phenomex, Macclesfield, UK). FollowingAvailable online http://breast-cancer-research.com/content/10/2/R32
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extraction, the metabolites were dried under vacuum, redis-
solved in 40% aqueous methanol and analysed using liquid
chromatography/mass spectrometry (Waters Quattro Ultima;
Waters, Manchester, UK). Samples were quantified using tri-
ply  13C-labelled internal standards. The average intra-assay
coefficient of variation for serum analytes ranged from 2.8%
(enterolactone) to 20.0% (glycitein). Limits of detection for
serum phytoestrogens ranged from 0.04 ng/ml for daidzein to
0.11 ng/ml for equol, corrected for the concentration of sam-
ple [22]. The 284 serum samples that had been quantified for
the previous study [22] were designated Batch 1 for statistical
analysis, leaving 905 serum samples designated as Batch 2.
Spot urine samples were analysed for the same phytoestro-
gens as the serum samples. Three hundred and thirty-three
urine samples were analysed using isotope dilution gas chro-
matography/mass spectrometry, wherein dried extracts were
derivatised to their trimethylsilyl derivatives and were desig-
nated Batch 1 as before. The remaining 731 samples (Batch
2) were analysed by liquid chromatography/mass spectrome-
try, in which the dried extracts were redissolved in 40% aque-
ous methanol and were analysed as above. The limits of
detection with gas chromatography/mass spectrometry after
correction for dilution of sample ranged from 1.8 ng/ml
(enterodiol) to 8.0 ng/ml (enterolactone). For liquid chroma-
tography/mass spectrometry, the limit for detection ranged
from 0.08 ng/ml for daidzein to 0.22 ng/ml for equol. The intra-
assay coefficient of variation for urinary phytoestrogens
ranged from 2.3% (daidzein) to 6.8% (equol). Details of the
quality assurance and methodology have been published else-
where [31].
Statistical methods
For case–control comparisons of potential confounders, a chi-
square test was applied to categorical variables and an
unpaired Student t test was conducted for continuous varia-
bles (log-transformed). To be retained in the log transforma-
tion, the value 0.011 was assigned arbitrarily for
phytoestrogen levels below the level of reliable quantification,
and the value 0.01 was when the compound was not detected
at all. Pearson correlation coefficients were calculated to
ascertain the relationship between log-transformed urinary
and serum measures of each phytoestrogen. The Wilcoxon–
Mann–Whitney test was applied to determine whether the
probability distribution for serum and urinary phytoestrogens
differed between cases and control individuals.
Odds ratios for breast cancer risk were calculated using
unconditional logistic regression. Summary variables of total
lignans (enterodiol and enterolactone) and total isoflavones
(daidzein, genistein, O-DMA, equol, and glycitein) were cre-
ated and analysed in conjunction with individual phytoestro-
gens. Phytoestrogen values were log2-transformed, so the
estimates of risk correspond to a doubling in phytoestrogen
level [32]. All models were adjusted for batch and for variables
related to oestrogen exposure: age at menarche (continuous),
parity (ordinal), breastfeeding (categorical), history of oral con-
traceptive use (categorical), menopausal hormone therapy use
(categorical), and menopausal status (categorical). Additional
potentially confounding variables were retained in the analysis
if the likelihood ratio test yielded a significant P value or if the
β values for the phytoestrogen in the model were modified by
1 0 %  o r  m o r e  w h e n  a d d e d  i n d i vidually to the model. This
approach identified weight (continuous), fat (continuous),
energy (continuous), family history of breast cancer (categori-
cal), and social class (categorical) as covariates. Smoking sta-
tus (categorical), education (categorical), fibre intake
(continuous), height (continuous), and physical activity level
(categorical) were found to be nonsignificant covariates and
were therefore not included in the final models. Among sub-
jects with oestradiol data available, adjustment for oestradiol
(continuous) did not alter the β values for the phytoestrogens
under examination and was therefore not included in the final
models.
Covariates were missing for fewer than 5% of the sample
unless specified otherwise; subjects with missing covariate
data were deleted from the analysis. Analyses were repeated
for cases with tumours that were identified as ER-positive and
their controls. The small number of participants with ER-nega-
tive tumours precluded analysis of this subgroup. To further
explore the role of oestrogen, the sample was stratified by
menopausal status (group 1, premenopausal and perimeno-
pausal women; group 2, 2 years or more since last menstrual
cycle), and analyses were re-run on the subgroup with oestra-
diol data available.
All analyses were conducted with SAS software (version 8.02;
SAS Institute, Inc, Cary, NC, USA). All P values are two-sided;
values less than 0.05 were considered significant, with mar-
ginal significance noted below 0.1.
Results
Demographic and lifestyle characteristics of the 237 breast
cancer cases and 952 control individuals are presented in
Table 1. The mean length of follow-up was 9.5 years (standard
deviation, approximately 3.1 years), representing 11,261 per-
son-years. In the population of analysis, 80% were postmeno-
pausal and 65% reported that they had breastfed (Table 1).
The frequency of family history of breast cancer, social class,
and smoking did not differ across cases and controls. Relative
to the control individuals, breast cancer cases reported higher
mean weight, fat and energy intake, and marginally higher
oestradiol levels. Use of oral contraceptive was distributed dif-
ferently between cases and controls.
The median serum and urinary phytoestrogen levels are pre-
sented in Table 2. Cases and controls had significantly differ-
ent distributions of serum equol, serum and urinary glycitein,
and serum enterodiol; marginal differences were observed forBreast Cancer Research    Vol 10 No 2    Ward et al.
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Table 1
Characteristics of the breast cancer case – control sample in the European Prospective into Cancer-Norfolk cohort
Cases (n = 237) Controls (n = 952) P valuea
Age (years) 58.5 (8.6) 58.7 (8.9) 0.791
Weight (kg) 69.2 (11.4) 67.7 (11.2) 0.068
Energy intake (kcal/day) 1745.9 (386.6) 1678.6 (385.2) 0.022
Fat intake (g/day) 66.5 (19.7) 63.5 (20.1) 0.038
Alcohol intake (g/day) 8.6 (12.1) 7.8 (11.2) 0.179
Oestradiol (pmol/l)b 173.1 (341.3) 136.9 (259.4) 0.066
Age at menarche (years) 12.8 (1.6) 13.0 (1.5) 0.058
Family history of breast cancer: yes 23 (10%) 74 (8%) 0.216
Breastfed children: yes 155 (65%) 617 (65%) 0.865
Number of children
0 38 (16%) 117 (12%) 0.174
1 26 (11%) 134 (14%)
2 103 (43%) 398 (42%)
3 57 (24%) 218 (23%)
4+ 13 (6%) 85 (9%)
Menopausal statusc
Premenopausal 28 (12%) 123 (13%) 0.569
Perimenopausal 15 (6%) 51 (5%)
Postmenopausal 1 57 (24%) 195 (21%)
Postmenopausal 2 137 (58%) 583 (61%)
Menopausal hormone therapy use
Current 63 (27%) 207 (22%) 0.256
Former 30 (13%) 118 (12%)
Never 144 (61%) 627 (66%)
Oral contraceptive use
Current 9 (4%) 13 (1%) 0.041
Former 98 (41%) 419 (44%)
Never 130 (55%) 520 (55%)
Social class
Professional/manager 105 (45%) 405 (42%) 0.620
Skilled nonmanual 46 (20%) 171 (18%)
Skilled manual 51 (22%) 197 (21%)
Semi-skilled/nonskilled 20 (9%) 112 (12%)
Missing/unclassified 15 (4%) 67 (7%)
Smoking status
Current 26 (11%) 94 (10%) 0.822
Former 70 (30%) 297 (32%)
Never 137 (59%) 550 (59%)
Data presented as mean ± standard deviation or n (column percentage). aP values obtained with a t test for continuous values and a chi-square test for categorical 
variables. bOestradiol data availability: serum phytoestrogens, 153 cases and 603 controls (51 cases and 185 controls among the oestrogen receptor-positive 
subgroup); urinary phytoestrogens, 141 cases and 543 controls (49 cases and 171 controls among the oestrogen receptor subgroup). cPerimenopausal, <1 year 
since last menstrual cycle; postmenopausal 1, 2 to 5 years since last menstrual cycle; postmenopausal 2, 5 years or more since last menstrual cycle.Available online http://breast-cancer-research.com/content/10/2/R32
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serum enterolactone and urinary genistein. When the analysis
was restricted to the ER subgroup, urinary enterolactone was
distributed differently between cases and controls; marginal
differences were detected for urinary glycitein and equol, and
there were no differences observed for serum phytoestrogens.
Of the precursor isoflavones, genistein was found in greater
Table 2
Mean and median serum and urinary phytoestrogen levels in the European Prospective into Cancer-Norfolk breast cancer case – 
control study
Median % detected Median % detected P valuea
Full study Controls (n = 952) Cases (n = 237)
Serum (ng/ml)
Genistein 5.00 91 4.77 93 0.608
Daidzein 2.00 86 1.98 91 0.206
E q u o l 0 . 0 12 9 0 . 0 13 3 0 . 0 0 5
o-Desmethylangolensin 0.10 52 0.10 59 0.284
Glycitein 0.01 29 0.01 40 <0.0001
Enterodiol 0.10 58 0.20 68 0.023
E n t e r o l a c t o n e 5 . 8 39 8 5 . 0 09 8 0 . 0 8 8
Urine (μg/mmol creatinine) Controls (n = 851) Cases (n = 213)
Genistein 5.71 84 6.47 86 0.071
Daidzein 14.82 92 14.63 94 0.134
Equol 0.011 47 0.011 52 0.403
o-Desmethylangolensin 0.92 73 0.58 75 0.486
Glycitein 0.62 69 1.29 79 <0.0001
Enterodiol 6.45 86 7.25 91 0.188
Enterolactone 112.70 97 102.07 97 0.366
Oestrogen receptor-positive subgroup Controls (n = 381) Cases (n = 112)
Serum (ng/ml)
Genistein 4.80 89 4.55 89 0.446
Daidzein 1.83 84 1.89 87 0.846
E q u o l 0 . 0 13 7 0 . 0 14 1 0 . 6 3 7
o-Desmethylangolensin 0.10 51 0.10 56 0.569
G l y c i t e i n 0 . 0 12 5 0 . 0 12 9 0 . 3 7 2
Enterodiol 0.10 59 0.17 61 0.645
E n t e r o l a c t o n e 6 . 6 09 8 6 . 2 59 8 0 . 7 3 9
Urine (μg/mmol creatinine) Controls (n = 344) Cases (n = 102)
Genistein 5.67 84 4.74 80 0.675
Daidzein 15.30 93 13.09 92 0.948
E q u o l 0 . 0 45 1 0 . 4 66 1 0 . 0 7 3
o-Desmethylangolensin 1.29 70 1.02 72 0.899
G l y c i t e i n 0 . 5 16 5 0 . 5 67 0 0 . 1 9 5
Enterodiol 6.62 85 8.82 91 0.075
Enterolactone 123.99 97 136.55 99 0.044
aP value from the Wilcoxon – Mann – Whitney test.Breast Cancer Research    Vol 10 No 2    Ward et al.
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amounts than daidzein in serum, whereas daidzein was
present in higher concentration in urine (Table 2); this different
ratio has been noted previously [30]. After excluding those
cases and controls with values below the level of quantifica-
tion, the correlations between the serum values for each phy-
toestrogen (ng/ml) and the corresponding urinary values (μg/
mmol creatinine) were as follows: enterodiol, 0.67; enterolac-
tone, 0.79; equol, 0.63; daidzein, 0.75; genistein, 0.66; gly-
citein, 0.18; O-DMA, 0.72 – all correlations were significant at
P = 0.003. Correlations including values below the level of
quantification ranged from 0.27 to 0.58 (P < 0.0001).
None of the serum phytoestrogens were associated with the
risk of breast cancer, regardless of ER-positive tumour status.
In the full study, an increased risk of breast cancer was
observed with higher levels of total urinary isoflavones (Table
3). Among women with ER-positive tumours, the risk of breast
cancer was associated with higher levels of urinary equol lev-
els, and was marginally associated with greater exposure to
total urinary isoflavones (Table 3). The observed associations
were not affected by adjustment for oestradiol (data not
shown). After stratification, a stronger association with breast
cancer risk was detected for total urinary isoflavones among
premenopausal and perimenopausal women (odds ratio =
1.30 (95% confidence interval = 1.04 to 1.64), P = 0.022),
but was not significant among postmenopausal women (odds
ratio = 1.01 (95% confidence interval = 0.96 to 1.13), P =
0.372); no change in results was observed for serum phytoes-
trogens (data not shown). The small number of premenopau-
sal and perimenopausal women in the ER subgroup precluded
stratification by menopausal status.
Discussion
Despite the biological plausibility of a proposed reduction in
breast cancer risk with greater exposure to phytoestrogens [8-
12], the present analyses provided no evidence that phytoes-
trogen biomarkers were associated with decreased breast
cancer risk in the prospective EPIC-Norfolk cohort. The
Table 3
Association between phytoestrogen biomarkers and breast cancer risk in the European Prospective into Cancer-Norfolk study
Serum (ng/ml) Urine (μg/mmol creatinine)
Odds ratio 95% confidence interval P value Odds ratio 95% confidence interval P value
Full study (219 cases/891 controls) (198 cases/797 controls)
Total isoflavones 1.03 0.95 to 1.11 0.479 1.08 1.00 to 1.16 0.055
Total lignans 0.99 0.90 to 1.08 0.728 1.01 0.94 to 1.09 0.758
Daidzein 1.04 0.98 to 1.10 0.225 1.05 0.99 to 1.10 0.096
Equol 1.04 0.98 to 1.10 0.167 1.03 0.99 to 1.06 0.131
o-Desmethylangolensin 1.03 0.97 to 1.09 0.390 1.02 0.98 to 1.06 0.250
Genistein 1.00 0.94 to 1.05 0.911 1.01 0.97 to 1.05 0.706
Glycitein 1.03 0.97 to 1.10 0.345 1.03 0.98 to 1.07 0.248
Enterodiol 1.02 0.96 to 1.09 0.461 1.01 0.96 to 1.05 0.772
Enterolactone 0.98 0.91 to 1.05 0.564 0.99 0.94 to 1.04 0.718
Oestrogen receptor-positive subgroup (105 cases/365 controls) (95 cases/329 controls)
Total isoflavones 1.01 0.91 to 1.12 0.818 1.09 0.97 to 1.22 0.154
Total lignans 1.02 0.89 to 1.17 0.774 1.12 0.99 to 1.28 0.083
Daidzein 1.05 0.97 to 1.13 0.260 1.03 0.96 to 1.10 0.468
Equol 1.01 0.93 to 1.09 0.887 1.07 1.01 to 1.12 0.013
o-Desmethylangolensin 1.05 0.96 to 1.14 0.314 1.04 0.98 to 1.10 0.192
Genistein 0.99 0.92 to 1.06 0.775 1.00 0.94 to 1.05 0.882
Glycitein 1.03 0.93 to 1.13 0.614 1.04 0.98 to 1.10 0.186
Enterodiol 1.00 0.92 to 1.09 0.990 1.04 0.98 to 1.11 0.235
Enterolactone 1.01 0.91 to 1.14 0.806 1.08 0.98 to 1.19 0.115
Values are log2-transformed and adjusted for weight, oral contraceptive use, menopausal hormone treatment, menopausal status, parity, 
menarche, breastfeeding, family history of breast cancer, daily intake of fat and energy, and batch.Available online http://breast-cancer-research.com/content/10/2/R32
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present study was well positioned to examine this association
as the collection of biomarker samples prior to cancer diagno-
sis reduced the potential bias of health behaviour change in
response to disease diagnosis. The mass spectrometry quan-
tification method for samples used in the EPIC-Norfolk study
offers greater specificity and sensitivity than that provided by
time-resolved fluoroimmunoassay, the method commonly
applied in prior phytoestrogen biomarker research [31], and
was applied to a large variety of metabolites. Furthermore, with
data available on other aspects of diet, anthropometric meas-
urements, reproductive history, exogenous hormone use, and
circulating levels of oestradiol, the present analyses were able
to adjust for the majority of known risk factors for breast can-
cer risk. Nonetheless, the majority of the associations in the
present analysis were null.
The predominant absence of associations between phytoes-
trogen biomarkers and breast cancer may be attributed to lim-
itations specific to aspects of the study design. The half-life of
daidzein, genistein, and equol has been reported as <12 hours
[33]; the single samples of serum and urine drawn for analysis
would therefore have been influenced by variation in the diet
and in the gut microflora at the time of the health check and
may not have been representative of usual intake. In a study
with three yearly serum samples drawn over 2 years, the relia-
bility coefficients ranged from 0.11 (daidzein) to 0.55 (entero-
lactone) [34]; these results suggest that a single sample is
unlikely to represent usual intake. Furthermore, the exploration
of the ER status in relation to phytoestrogen biomarkers and
breast cancer risk may have been hampered by limited statis-
tical power due to the small number of cases with these data
available; the absence of ER status information for 40% of
breast cancer cases in the present study raises the question
of whether the associations observed for ER-positive cases
would have appeared differently had that information been
available for all subjects. Finally, it is possible that the biomar-
ker samples were drawn outside the time period relevant for
cancer development, as phytoestrogen intake prior to the mat-
uration of the mammary gland may exert the greatest influence
over breast cancer risk [35].
Increased risk with greater levels of urinary equol in the ER-
positive subgroup of the present study was among the few sig-
nificant associations detected; however, this association
should be interpreted with caution as it was not also observed
in the analysis of serum equol. This result is consistent with the
previous study of women in the EPIC-Norfolk cohort, wherein
breast cancer risk was positively associated with serum and
urinary equol [22], and with the fact that equol has been iden-
tified as a highly oestrogenic compound [15]. Furthermore, it
has been suggested that some phytoestrogens may be ago-
nists rather than antiestrogens in the presence of relatively
lower circulating levels of mammalian oestrogen [1,2], which
may have been the state of the postmenopausal majority in the
present study. Other studies have reported that serum equol
was not associated with breast cancer risk [25], whereas uri-
nary equol was associated with decreased risk [24]; however,
neither study examined ER status as an effect modifier.
The multiple comparisons conducted in the present analysis
may have created a false-positive finding for urinary equol in
the ER-positive group. This methodological concern also
applies to the marginally significant associations detected for
total urinary lignans in the ER-positive cohort and for total uri-
nary isoflavones in the full study. Additionally, the disparity
between urinary and serum results may have been affected by
fact that the proportion of participants with undetected values
was generally higher for phytoestrogen biomarkers in serum
compared with urine. Nonetheless, the evidence suggests that
there may be circumstances where phytoestrogen exposure
increases breast cancer risk, and thus deserves further study
The literature regarding a potential interaction between phy-
toestrogens and ER status in relation to breast cancer is lim-
ited and has not included a measure of equol. In a prospective
Danish case–control study, plasma enterolactone was not
associated with ER-positive breast cancer, but was associ-
ated with a decreased risk of ER-negative breast cancer; the
authors noted that, with only 80 ER-negative cases, caution is
warranted in interpretation of this result [36]. A prospective
study of postmenopausal women in the Netherlands found no
association between breast cancer and urinary genistein or
enterolactone regardless of ER status [27]; again, equol was
not assessed.
Studies of dietary measures of phytoestrogen in relation to ER-
positive cancer risk have been limited by the quality of data
available and by the range of phytoestrogens investigated. In
a large French prospective study including 1,469 breast can-
cer cases, ER-positive and progesterone-positive breast can-
cer risk was inversely related to an estimate for intake of total
dietary lignans (secoisolariresinol, matairesinol, pinoresinol,
and lariciresinol) [37]. Two studies from the United States
reported no association between dietary secoisolariciresinol
and matairesinol and breast cancer, regardless of menopausal
status or ER tumour status [38,39], with the exception of
reduced risk of ER-negative breast cancer among premeno-
pausal women with the highest level of intake [39]. Overall, fur-
ther exploration is evidently required before definitive
conclusions can be ascertained regarding the relationships
between ER status, breast cancer risk, and phytoestrogens,
particularly equol.
Only two prospective studies have examined a wide range of
metabolites with the same methods as the present study
[22,25]; all other studies were either retrospective or case–
control in design [16,19,20,23,26] and/or utilised methods
limited to one or two metabolites [16-21,27]. Among women
in the case–control study from the EPIC-Dutch cohort, higher
serum levels of genistein were related to a reduction in breastBreast Cancer Research    Vol 10 No 2    Ward et al.
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cancer risk, but there were no associations observed for gly-
citein, O-DMA, equol, enterodiol or enterolactone [25]. With
the exception of daidzein, the geometric mean serum phytoes-
trogen levels were slightly higher in the EPIC-Norfolk cohort.
The EPIC-Dutch and EPIC-Norfolk studies were comparable
in terms of study design and the quantification of their serum
samples, but dietary factors were evaluated and included as
potential confounders only in the EPIC-Norfolk cohort. Overall,
the studies were similar as the majority of findings were null.
Studies of phytoestrogen intake in western populations have
yielded inconsistent conclusions on the nature of the relation-
ship with breast cancer, with evidence of either decreased risk
[37,40] or no association [41,42]. Accordingly, reviews of the
epidemiological and experimental studies have not indicated a
clear consensus regarding the nature of phytoestrogen expo-
sure and breast cancer risk [43-47]. There is a great deal of
heterogeneity among these dietary studies in terms of study
design, the population examined, the type of phytoestrogens
under study, the coverage of phytoestrogen-rich foods in the
dietary questionnaires, and use of compiled data from various
sources for the calculation of phytoestrogen levels in food
[37,40]. Furthermore, phytoestrogens are a complex mixture
of different compounds found at very low levels in foods and
biological materials, and the analysis of foods is difficult due to
matrix effects and the presence of substantial variation
according to variety, crop, season and processing methods,
and the requirement of sensitive methods able to detect low
levels. In addition, phytoestrogens – particularly the lignans –
are found in foods rich in other plant-protective compounds
and it may not be possible to adequately correct for confound-
ing by other food constituents, such as the dietary fibre, flavo-
noids, and antioxidants found in these foods.
Overall, the absence of strong associations between phytoes-
trogen biomarkers and breast cancer in the present study
could indicate that the level of exposure was too low to yield
an effect on cancer development. It has been noted previously
that the intake of isoflavones is relatively low in the EPIC-Nor-
folk cohort [4]. The lower incidence of breast cancer that has
been observed in Asian populations may be attributed to a
higher intake of phytoestrogen-rich food, to higher levels of
phytoestrogen biomarkers, and to production of equol relative
to European populations [15,48-50]. Nonetheless, since it has
been estimated by direct analysis of a representative sample
of foods that there has been a small increase in intake of die-
tary isoflavones in the United Kingdom since the late 1980s
[51], the relationship between phytoestrogens and breast can-
cer may differ across generations and ought to be monitored.
Conclusion
The majority of the urinary or serum biomarkers for phytoestro-
gen levels were not associated with breast cancer risk in the
EPIC-Norfolk cohort. The limited evidence of an association
between urinary equol and ER-positive breast cancer cases
warrants further study in subsequent examinations of breast
cancer risk and phytoestrogen biomarkers. Overall, the
present study does not provide sufficient insight into the
nature of the relationship between phytoestrogens and breast
cancer risk to warrant modification of phytoestrogen intake
among those at risk for breast cancer.
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